Percutaneous Coronary Intervention

In patients with coronary artery disease and severe aortic stenosis undergoing transcatheter aortic valve replacement, those who also had PCI had better outcomes than those who had their CAD managed conservatively, researchers reported.

PHILADELPHIA — In patients with acute MI who had successful PCI and underwent imaging to assess plaque composition, diabetes raised risk for poor outcomes but the difference was not related to plaque, according to a presentation.

In two trials, OCT-guided PCI demonstrated superiority in imaging endpoints and improved procedural success compared with angiography and fluoroscopy alone, speakers reported.

In patients with ACS who underwent PCI with a drug-coated balloon, an antiplatelet therapy de-escalation strategy was noninferior to 12-month dual antiplatelet therapy, researchers reported at EuroPCR.

A percutaneous approach to treatment of severe aortic stenosis and complex CAD was superior to surgical valve replacement and CABG, a speaker reported.

Although the rate of heart attacks in the United States has declined by 50% in the last 20 years, patients from low-income households had significantly higher odds of mortality than patients from high-income households.

Use of radial access for PCI has increased greatly in the U.S. over the last decade and is associated with lower risk for mortality, bleeding and nonfatal vascular complications compared with a transfemoral approach, a speaker reported.

ATLANTA — Intravascular ultrasound-guided PCI lowered risk for target vessel failure vs. an angiography-guided approach for patients with acute coronary syndrome, a speaker reported.

ATLANTA — Preventive PCI plus optimal medical therapy was superior to optimal medical therapy alone for patients with nonflow-limiting vulnerable coronary plaques, according to the results of the PREVENT trial.

ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.